HOME >> MEDICINE >> NEWS
International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced that enrollment into a large international HIV/AIDS trial comparing continuous antiretroviral therapy with episodic drug treatment guided by levels of CD4+ cells has been stopped. Enrollment was stopped because those patients receiving episodic therapy had twice the risk of disease progression (the development of clinical AIDS or death), the major outcome of the study.

NIAID made the decision to halt enrollment in collaboration with the study's Executive Committee and following a recommendation received from an independent Data and Safety Monitoring Board (DSMB). The DSMB, charged with regularly evaluating data and safety issues during the multi-year trial, conducted a review of the interim study data in early January.

The trial, known as Strategies for Management of Anti-Retroviral Therapy, or SMART, was designed to determine which of two different HIV treatment strategies would result in greater overall clinical benefit. HIV-positive volunteers were assigned at random to either a viral suppression strategy, in which antiretroviral therapy (ART) was taken on an ongoing basis to suppress HIV viral load; or a drug conservation strategy, in which ART was started only when the levels of key immune cells, called CD4+ cells, dropped below 250 cells per cubic millimeter (mm3). Volunteers in the drug conservation group were taken off ART--with the aims of reducing drug side effects and preserving treatment options--whenever their CD4+ cells were above 350 cells/mm3. (For more details see http://www.smart-trial.org).

The trial involved an international collaboration of 318 clinical sites in 33 countries. It began enrollment in January 2002 and had successfully recruited more than 90 percent of its target of 6,000 participants: as of January 11, 2006, when enrollment was stopped,
'"/>

Contact: Laurie K. Doepel
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
18-Jan-2006


Page: 1 2 3 4

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Africa: International volunteer impact small, but significant
3. International Workshop on Cities, Science and Sustainability
4. International journal group updates guidelines on registration of clinical trials
5. International studies show high efficacy for HPV vaccine
6. Poorer countries could struggle to implement new International Health Regulations
7. Chinese space agency joins the International Charter Space and Major Disasters
8. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
9. International cooperation boosts EarthCARE
10. International award
11. International Best Cases Competition returns to Vancouver

Post Your Comments:
(Date:4/23/2014)... identified an important enzyme pathway that helps prevent new ... a condition that has been directly linked to cancer ... biochemistry, found that near the end of cell division, ... any breaks in DNA are fully repaired before the ... cells. This process helps safeguard against some of the ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... April 21, 2014 Five for-profit and non-profit ... $1.25 million in Proof of Concept grants to ... into commercial products, the Life Sciences Discovery Fund ... Entrepreneur Mentoring Program grant to the Washington Biotechnology ... advisory network to train the next generation of ...
(Date:4/23/2014)... known as Ritalin, may prevent the depletion of self-control, ... a journal of the Association for Psychological Science. , ... or trying to focus attention on a boring textbook ... potential explanation for this difficulty: Exerting self-control for a ... self-control effectively on subsequent tasks. , "It is as ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to ... much as 50 percent. When coupled with an innovative ... the device facilitated the complete elimination of seizures in ... the decade-long clinical trials. , That,s good news for ... the U.S. living with epilepsy whose seizures can,t be ...
Breaking Medicine News(10 mins):Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
(Date:1/14/2014)... Md. , Jan. 14, 2014   Evidera , ... industry, announced that the Center for Drug Evaluation and ... its first draft qualification guidance document for a patient-reported ... Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for Measurement ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
Cached News: